Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,941 to 1,960 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Light, chromatin, action: nuclear events regulating light signaling in Arabidopsis. | New Phytol | 2022 | 35949052 | PubTator, text mining | PubMed |
A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies. | J Clin Lab Anal | 2022 | 35949000 | PubTator, text mining | PubMed |
| Mettl14-driven senescence-associated secretory phenotype facilitates somatic cell reprogramming. | Stem Cell Reports | 2022 | 35947961 | PubTator, text mining | PubMed |
| Role of m6A writers, erasers and readers in cancer. | Exp Hematol Oncol | 2022 | 35945641 | PubTator, text mining | PubMed |
| Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma. | Cell Death Discov | 2022 | 35945194 | PubTator, text mining | PubMed |
| TRABID targets DDB2 for deubiquitination to promote proliferation of hepatocellular carcinoma cells. | Biochem Biophys Res Commun | 2022 | 35944360 | PubTator, text mining | PubMed |
| RNA 5-methylcytosine status is associated with DNMT2/TRDMT1 nuclear localization in osteosarcoma cell lines. | J Bone Oncol | 2022 | 35942470 | PubTator, text mining | PubMed |
| M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. | BMC Cancer | 2022 | 35941582 | PubTator, text mining | PubMed |
| Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. | BMC Bioinformatics | 2022 | 35941550 | PubTator, text mining | PubMed |
| Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents. | J Med Chem | 2022 | 35939803 | PubTator, text mining | PubMed |
| RNA m6A demethylase ALKBH5 regulates the development of γδ T cells. | Proc Natl Acad Sci U S A | 2022 | 35939687 | PubTator, text mining | PubMed |
| Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. | Front Genet | 2022 | 35938001 | PubTator, text mining | PubMed |
| Research Progress for RNA Modifications in Physiological and Pathological Angiogenesis. | Front Genet | 2022 | 35937999 | PubTator, text mining | PubMed |
| N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma. | Front Genet | 2022 | 35937991 | PubTator, text mining | PubMed |
| The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer. | Front Oncol | 2022 | 35936737 | PubTator, text mining | PubMed |
| Development of a Novel Prognostic Model of Glioblastoma Based on m6A-Associated Immune Genes and Identification of a New Biomarker. | Front Oncol | 2022 | 35936722 | PubTator, text mining | PubMed |
| Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma. | Front Oncol | 2022 | 35936671 | PubTator, text mining | PubMed |
| Bioinformatics Analysis Revealing the Correlation between NF-κB Signaling Pathway and Immune Infiltration in Gastric Cancer. | Comput Math Methods Med | 2022 | 35936362 | PubTator, text mining | PubMed |
| METTL3 inhibits inflammation of retinal pigment epithelium cells by regulating NR2F1 in an m6A-dependent manner. | Front Immunol | 2022 | 35936005 | PubTator, text mining | PubMed |
| RNA m6A modification orchestrates the rhythm of immune cell development from hematopoietic stem cells to T and B cells. | Front Immunol | 2022 | 35935968 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=98